Want to see AU:CHM full AI Analyst Report?
CHM Stock Chart & Stats
AU$0.01
<AU$0.01(5.13%)
At close: 4:00 PM EDT
AU$0.01
<AU$0.01(5.13%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.24
Previous CloseN/A
Volume45.00K
Average Volume (3M)983.95K
Market Cap
AU$442.39K
Enterprise ValueAU$3.44M
Total Cash (Recent Filing)AU$800.14K
Total Debt (Recent Filing)AU$679.85K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding147,461,980
10 Day Avg. Volume1,729,759
30 Day Avg. Volume983,949
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.26
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$480.58M
Bulls Say, Bears Say
Bulls Say
Specialized CAR-T Oncology FocusA focused oncology cell-therapy strategy gives Chimeric a clear therapeutic identity and aligns its research with a significant unmet medical need. If clinical translation succeeds, concentrated expertise in CAR-T could support differentiated programs and longer-term partnering or commercialization opportunities.
Modest Reported DebtReported debt remains modest in absolute terms, which avoids adding a large interest burden to the company’s already loss-making operations. This provides some structural balance-sheet support, although negative equity and cash burn still materially limit financial flexibility.
Historical Gross-profit PotentialStrong gross profit in earlier periods indicates that the company has previously demonstrated potential for favorable economics within its reported activities. That history does not offset the latest revenue collapse, but it provides a basis for assessing whether future programs can regain operating traction.
Bears Say
Revenue Has Collapsed To Near-zeroThe latest revenue collapse materially weakens the operating foundation and suggests that current activities are not generating a dependable commercial income stream. Without a sustained recovery, Chimeric remains reliant on funding or successful development milestones to support ongoing operations.
Persistent And Sizable LossesRecurring operating and net losses show that the business has not yet converted its development activities into sustainable profitability. Continued losses can consume resources needed for clinical progress and increase dependence on future capital raising or other external funding.
Negative Equity And Ongoing Cash BurnDeeply negative operating cash flow, combined with negative shareholder equity, indicates limited self-funding capacity and a weakened financial base. This raises the likelihood that continued research and development will require external financing, creating meaningful funding and dilution pressure.
Chimeric Therapeutics Ltd. News
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.24 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Chimeric Therapeutics Ltd.’s market cap is AU$442.39K.
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 130 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.606 earnings per share for the quarter.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 147,461,980 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.606 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Chimeric Therapeutics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
349.88%
Trailing 12-Months
Asset Growth
-94.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Technical Analysis
Imugene
―
Living Cell Technologies
―
Mesoblast Limited
―
Immutep Ltd
―
Regeneus Ltd.
―